Treatment with the disease modifying anti-rheumatic drug methotrexate in dosages of 10–15 mg/m2 given once weekly has been proven to be safe and effective in Juvenile Idiopathic Arthritis, as well as etanercept. With this regime it is possible to achieve clinical remission on and off medication but the best time to stop MTX after remission has not yet been established. The present trial was designed to determine if the time to discontinuation of methotrexate (6 versus 12 months) in Juvenile Idiopathic Arthritis, after the patient has reached clinical remission, influence the time to relapse, the clinical course and the predictors of flare.

Demirkaya E, Lanni S, Bovis F, Galasso R, Ravelli A, Palmisani E, Consolaro A, Pederzoli S, Marafon D, Simianer S, Martini A, Ruperto N, Pistorio A for the Paediatric Rheumatology International Trials Organisation (PRINTO)
A meta-analysis to estimate the placebo effect in juvenile idiopathic arthritis in randomized controlled trials.
Arthritis Rheum 2016;68:1540-1550.
Year: 2016 -

 Ask for reprints

Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Rua Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur-Zielinska H, Tauber T, Martini A, Foell D for the Paediatric Rheumatology INternational Trials Organization (PRINTO).
Phagocyte-specific S100 proteins and high-sensitivity C-reactive protein as biomarkers for a risk-adapted therapy to maintain remission in juvenile idiopathic arthritis: a comparative study.
Ann Rheum Dis 2012;71:1991-1997
Year: 2012 -

 Ask for reprints

Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, Silverman ED, Balogh Z, Henrickson M, Davidson J, Foeldvari I, Imundo L, Simonini G, Oppermann J, ShenYK, Visvanathan S, Fasanmade A, Mendelsohn A, Martini A, Giannini EH for the Paediatric Rheumatology INternational Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension.
Ann Rheum Dis 2010:69(4):718-722
Year: 2010 -

 Ask for reprints

Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerß J, Stanevicha V, Mihaylova D, Ferriani V, Kanakoudi Tsakalidou F, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, García-Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J for the Paediatric Rheumatology INternational Trials Organization (PRINTO).
Comparison of 6-month vs 12-month withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission: a randomized controlled trial.
JAMA 2010; 303(13):1266-1273
Year: 2010 -

 Ask for reprints

Vilca I, Munitis PG, Pistorio A, Ravelli A, Buoncompagni A, Bica B, Campos L, Häfner R, Hofer M, Ozen S, Huemer C, Bae SC, Sztajnbok F, Arguedas O, Foeldvari I, Huppertz HI, Gamir ML, Magnusson B, Dressler F, Uziel Y, van Rossum MAJ, Hollingworth P, Cawkwell G, Martini A, Ruperto N for the Pediatric Rheumatology International Trials Organisation (PRINTO).
Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis. Analysis of the printo methotrexate trial.
Ann Rheum Dis 2010;69:1479-1483.
Year: 2010 -

 Ask for reprints

Wallace CA, Ruperto N, Giannini E
Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
J Rheumatol 2004 Nov;31(11):2290-4
Year: 2004 -

 Ask for reprints

Foell D, Frosch M, Zur Wiesch AS, Vogl T, Sorg C, Roth J
Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop?
Ann Rheum Dis 2004; 63(2):206-208
Year: 2004 -

 Ask for reprints